-
Article
Open AccessAuthor Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
-
Article
Open AccessAmivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) often develop resistance to current standard third-generation EGFR tyrosine kinase inhibitors (TKIs); no targeted t...
-
Article
Open AccessNeoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
In an ongoing, open-label, single-arm phase II study (NCT02927301), 181 patients with untreated, resectable, stage IB–IIIB non-small cell lung cancer received two ...
-
Article
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-...
-
Protocol
Managing a Large-Scale Multiomics Project: A Team Science Case Study in Proteogenomics
Highly collaborative scientists are often called on to extend their expertise to different types of projects and to expand the scope and scale of projects well beyond their previous experience. For a large-sca...
-
Article
Open AccessProtein-altering germline mutations implicate novel genes related to lung cancer development
Few germline mutations are known to affect lung cancer risk. We performed analyses of rare variants from 39,146 individuals of European ancestry and investigated gene expression levels in 7,773 samples. We fin...
-
Article
Open AccessProteogenomic landscape of squamous cell lung cancer
How genomic and transcriptomic alterations affect the functional proteome in lung cancer is not fully understood. Here, we integrate DNA copy number, somatic mutations, RNA-sequencing, and expression proteomic...
-
Article
Open AccessK27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
BRAF plays an indispensable role in activating the MEK/ERK pathway to drive tumorigenesis. Receptor tyrosine kinase and RAS-mediated BRAF activation have been extensively characterized, however, it remains und...
-
Article
Open AccessPhase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
Bypass activation of Src family kinases can confer resistance to EGFR tyrosine kinase inhibitors (TKIs) based on preclinical models. We prospectively assessed the safety and clinical activity of dasatinib and ...
-
Article
Open AccessRandomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
Small cell lung cancer TP53 mutations lead to expression of tumor antigens that elicits specific cytotoxic T-cell immune responses. In this phase II study, dendritic cells transfected with wild-type TP53 (vaccine...
-
Protocol
The Galaxy Platform for Reproducible Affinity Proteomic Mass Spectrometry Data Analysis
Affinity proteomics (AP-MS) is growing in importance for characterizing protein-protein interactions (PPIs) in the form of protein complexes and signaling networks. The AP-MS approach necessitates several diff...
-
Article
Open AccessA phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma
The GM.CD40L vaccine, which recruits and activates dendritic cells, migrates to lymph nodes, activating T cells and leading to systemic tumor cell killing. When combined with the CCL21 chemokine, which recruit...
-
Article
Open AccessIdentification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk
Genome-wide association studies (GWAS) identified the chromosome 15q25.1 locus as a leading susceptibility region for lung cancer. However, the pathogenic pathways, through which susceptibility SNPs within chr...
-
Article
Development of a Targeted Smoking Relapse-Prevention Intervention for Cancer Patients
We describe the series of iterative steps used to develop a smoking relapse-prevention intervention customized to the needs of cancer patients. Informed by relevant literature and a series of preliminary studi...
-
Article
Polypharmacology-based ceritinib repurposing using integrated functional proteomics
A systems chemical biology approach to characterize beneficial off-target effects revealed a polypharmacology mechanism for the multikinase inhibitor ceritinib and a repurposing opportunity through rational de...
-
Article
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
Christopher Amos and colleagues perform genome-wide association analysis for lung cancer using cohorts genotyped on the OncoArray and combing these with existing data. They identify 18 loci, 10 of which are ne...
-
Article
Open AccessCollateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer
Drug resistance remains an elusive problem in cancer therapy, particularly for novel targeted therapies. Much work is focused upon the development of an arsenal of targeted therapies, towards oncogenic driver ...
-
Article
Open AccessMEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Lung cancer is the leading cause of cancer deaths, and effective treatments are urgently needed. Loss-of-function mutations in the DNA damage response kinase ATM are common in lung adenocarcinoma but directly ...
-
Article
Open AccessA phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
This phase I study was carried out to determine the phase II recommended dose of tasisulam sodium (hereafter, tasisulam), a novel anticancer agent with a unique mechanism of action.
-
Article
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Determining relevant targets of promiscuous kinase inhibitors has proven difficult. A combination of two mass spectrometry–based proteomic approaches, RNAi depletion and rescue studies with drug-resistant muta...
